Med-X Inc

Med-X has created a portfolio of proprietary products and services which are designed to provide safer, yet effective solutions to many dangers we all face in our everyday lives. Our flagship product lines, Nature-Cide, Thermal-Aid and Malibu Brands already hold large scale domestic distribution positions in professional pest control and OTC pharmacy, respectively. In 2023 the Company along with its distribution partners are looking to position Nature-Cide into 32 different countries where the Company’s distribution partners are already doing a great deal of business.

Bookmarks

Raised 0 % of minimum

Funding Raised

$0

Funding Goal

$10,000-$3,000,000

Days Left to Invest

Closed

Invest Now

Med-X Inc

Med-X has created a portfolio of proprietary products and services which are designed to provide safer, yet effective solutions to many dangers we all face in our everyday lives. Our flagship product lines, Nature-Cide, Thermal-Aid and Malibu Brands already hold large scale domestic distribution positions in professional pest control and OTC pharmacy, respectively. In 2023 the Company along with its distribution partners are looking to position Nature-Cide into 32 different countries where the Company’s distribution partners are already doing a great deal of business.

Raised 0 % of minimum

Funding Raised

$0

Funding Goal

$10,000-$3,000,000

Days Remaining

Closed

Invest Now

Business Description

KEY INVESTMENT POINTS

Record Growth in 2022. Company saw 80% growth in revenue in 2022.
Planning an IPO in 2023 to gain access to committed $100MM in growth capital from Global Emerging Markets.
Reserved Nasdaq ticker symbol (MXRX).
Pesticide regulations continue to tighten around the world.
Climate changes increasing need for innovative pest control solutions.
Mosquitos becoming resistant to traditional chemical-based solutions.

In January 2023 the Nature-Cide division attended the Target Specialty Products / multi-billion dollar Rentokil North America National Sales Meeting and the division is already beginning to see the effects of the multi-billion dollar Rentokil Initial – Terminix merger that took place in late 2022. The Nature-Cide division is already staging registration into all of the Caribbean islands. The Nature-Cide division is also expecting to start the same process into Latin America as well as being approved on the Terminix and multi-billion dollar Rentokil North America’s Approved Product List (APL) in early to mid-2023, which should lead the Nature-Cide division into thousands of service trucks nationally.

$100M Commitment of Growth Captial from Global Emerging Markets (GEM)

In late 2021 the Company secured a $100 million capital commitment from Global Emerging Markets, a Luxembourg-based alternative investment group. Due to the Company’s continued revenue growth the investment banking community has recognized the continued demand for the Med-X product selection as well as large investor demand to participate in investment strategies that make an impact on health and ecology. The company investor base has surpassed 3,800 shareholders who have supported the Company’s mission since inception. Now that the Company has secured large scale capital to advance the business model, management is negotiating with the investment banking community to Underwrite an Initial Public Offering.

Now you can join the Green Scene movement that is making a difference in the areas of Health, Wellness and Ecology everyday, while management prepares the Company for expansion. This round of Regulation Crowdfunding will continue to support revenue growth of its brand portfolio, help position the Nature-Cide brand into the demanding world-wide markets while developing exciting new products and pursue acquisition opportunities, as the Company continues to draw awareness of the overuse of toxic synthetic chemicals and addictive pharmaceutical products.

Problem

WE ARE ALL BEING EXPOSED TO DANGEROUS SYNTHETIC CHEMICALS

Nearly everyone on this planet is exposed to pesticides or has taken a pain relief pill. Science has proven the long-term health complications and diseases that can happen as a result. Yet, too few people are aware that alternative Eco-friendly products and methods exist in the market that do a similar job, with the same type of efficacy, but with zero negative impact to oneself or the environment.

Reports estimate that in the United States alone over 20 billion pounds of pesticides have been sprayed on our properties and food in just the last 20 years. Globally in the same timespan, this industry has generated over $1 Trillion in revenues. So, why are we all so exposed?

Historically, the use of synthetic chemicals in all of our food, drugs, products, and industries has been controlled by a small group of very large and powerful international corporations. These corporations hold patents and spend millions of dollars lobbying governments all over the world to make sure their products are deemed safe for use, even though the long-term effects of exposure have been proven to be unhealthful and dangerous.

1 BILLION POUNDS OF PESTICIDES ARE USED IN THE USA EACH YEAR

Most of these synthetic chemicals contain strong toxic/poisonous chemicals with proven long-lasting, devastating carcinogenic effects. These compounds can take generations to become nascent in the environment. As more chemicals are sprayed or used in products, the build-up just keeps compounding the pollution that harms the environment.

Chemicals from plastics and pesticides are now beginning to be found in our groundwater and public drinking water supplies for the first time. No wonder numerous studies are now linking diseases such as Parkinson’s disease, asthma, cancer, and reproductive dysfunction to chemical pesticides.

Source: https://www.usgs.gov/centers/oki-water/science/pesticides?qt-science_center_objects=0#qt-science_center_objects

29% OF ALL PEOPLE WHO ARE PRESCRIBED OPIOIDS END UP MISUSING THEM AND 12% OF ALL PEOPLE PRESCRIBED OPIOIDS BECOME ADDICTED

We all know a family that has been impacted by the Opioid Public Health Crisis the Pharmaceutical conglomerates have directly caused in this country by using similar unethical tactics of lobbying to get their addictive drugs in the hands of as many everyday Americans as possible. These addictive drugs have been marketed for the use of everyday pain when science clearly proves the addictive nature of the chemicals used to make them.

Source: https://www.drugabuse.gov/drug-topics/opioids/opioid-overdose-crisis

Solution

MAKING A DIFFERENCE ONE COMMUNITY AT A TIME

Med-X has developed multiple all-natural plant-based brands of products that solve the same everyday issues people have been trying to solve with chemicals. Med-X has been selling these products into the homes of everyday Americans through partnerships with our e-commerce, major retail, healthcare and chemical distributors. The company is constantly marketing and educating the public about the dangers we face while at the same time offering real, proven effective, safe solutions.
Through targeted marketing, national distribution venues and exposure through our media divisions, our high margin proprietary products are cutting through the noise and getting mainstream attention and sell-through. Med-X is also on the cutting edge of green product development by introducing new innovative topical and supplement products, which will also become available to consumers in the future.

Our Mission

We would love to tell you that our green solution products and services will bring down Big Chemical and Big Pharma., but let’s be real – that is not going to happen. The point of this mission, in fact, is more about balance, transparency, and responsibility. Our goal here is to simply offer alternatives in markets that frankly have never been embraced as safe and effective natural options. And as you are aware, our thinking and products are beginning to resonate.

Safe Is The New Normal

We are at the forefront of providing safer alternatives to Big Chemical and Big Pharma that will make them more accountable. The consumer is demanding it. Times have changed. If you can offer a person the choice between a green solution and a chemical one, most Americans will now choose the green option, so long as it offers similar results. In recent surveys It’s proven that most Americans will actually pay substantially more for a safer option.

Thankfully, the products Med-X produces fall in line with middle America values. The Company has sourced product ingredients and focused on low-cost manufacturing techniques that enable us to offer these products at favorable costs to consumers, while holding higher margins for stakeholders.
In the past, there were little or no options for a homeowner to choose an effective green pesticide to be used in their home. Likewise, there were limited safe, drug-free options for truly relieving a migraine headache or everyday chronic pain. Now there are multiple options being offered by our Med-X Divisions and more that are in final development by Med-X scientists, doctors, and formulators. These products are proven effective in clinical trials and many are already in national distribution channels with solid sell-through driving continued growth.

Source: https://www.surveymonkey.com/stories/SM-366ZZGPJ/

Business Model

DIVERSE PORTFOLIO OF PRODUCTS AND SERVICES

Med-X is an innovator and leader in developing all-natural and alternative solutions to outdated poisonous chemicals and harmful pharmaceutical products, often used in pest control and pain management. Med-X incorporates best-in-class science, research, and technology for manufacturing and service capabilities across pest control, pain management, and aromatherapy, by primarily utilizing essential oil product development.

The Company’s sales are represented by multiple commercial sales verticals and third-party service providers managed through various domestic distribution partners. Retail sales are currently conducted by over-the-counter pharmacy retailers and various e-commerce service providers. Med-X is also focused on educating the public by supporting its digital media platforms The Marijuana Times and The National Investor Network.

Med-X has built a portfolio of high-margin commercial and consumer product brands as well as pest control services. These proven brands help drive the company’s current revenue growth. This portfolio strategy gives the company flexibility and power to scale up operations, and raise revenues in any sector by acquiring other like-minded brands that fit the company mission and would like the opportunity to grow together. The Company is already in exploratory talks with several small to medium-sized companies who have shown interest in being a part of a bigger green movement.

Market Projection

PEST MANAGEMENT MARKET OVERVIEW

Growth: $18 billion in 2018 and expected to surge to $27 billion by 2025.
Driving factors: Government regulations on food hygiene, public health, environmental health, growing awareness.
Restraining factors: Lack of skilled technicians, delayed regulatory approval process for chemical products.
Opportunity: Products that fall under the less-regulated FIFRA 25(b) Minimum Risk Pesticide category.

Source: https://www.alliedmarketresearch.com/pest-control-market

Competition

Med-X’s flagship divisions and core products are all based upon proprietary products which are all-natural, Eco-friendly, and highly effective for professional use while also not being cost prohibitive. The proven effectiveness and acceptance in the marketplace not only give our products the ability to go head-to-head with synthetic and pharmaceutical products and methods, but it also differentiates us from what is currently being implemented in this all-natural movement. Over the last two years, Med-X has broken out of the start-up stage and has become an emerging growth Company, as you can see by the revenue over the last two years.

Nature-Cide’s proprietary insecticide products are proven as effective as synthetic chemical pesticides in the field and in laboratory studies as well as anecdotal reports which have come in from all over the country and world. Unlike any other natural pesticide developer, Nature-Cide’s initial development was conducted in the field by our own in-house service division, Nature-Cide Services, Inc. Nature-Cide products are one of the fastest-growing natural products for professional pest management services in the world.

Thermal-Aid’s products are patented, all-natural and proven to reduce pain and drug usage in clinical studies. One study reveals Thermal-Aid arthritis hot/cold packs hold vital temperatures longer and steadier than what doctors use in rehabilitation centers. Unlike any other similar products in the space, all Thermal-Aid products carry Flexible Spending Accounts for Consumers and Patient Insurance coverage.

Malibu Brands’ “Pacific Pain Relief Cream” is this division’s first product release of many to come based upon a very unique and proprietary essential oil blend which is based upon migraine headache relief. In limited release, the anecdotal reports from users claiming unprecedented non-pharmaceutical pain relief has been overwhelming. This first release was developed to go head to head against CBD pain management products and will also be introducing a proprietary version containing various CBD and CBG essential oils when the Federal Government passes legislation for CBD and CBG compounds to be legally sold in the United States. A complete product line for Malibu Brands is currently in development and will be ready for release in late 2023 and 2024.

Traction & Customers

NATIONAL PEST CONTROL AND HEALTHCARE DISTRIBUTION

Nature-Cide is being used by a growing network of commercial customers including well known licensed pest control companies which operate nationally. Nature-Cide currently supplies Veseris, Forshaw, Ensystex and Target Specialty Products, along with its parent company “Rentokil Initial” in various regions including India and the Philippines. The Company is currently negotiating with Rentokil Initial Corporate in the U.K. to bring the Nature-Cide brand into 32 countries over the next two years.

The Company plans to continue aggressively marketing within the Pest Control, Hospitality, Transportation, Agriculture, and Janitorial supply markets, while also pursuing the implementation of Nature-Cide in state and federal facilities throughout various regions in the United States and beyond.

OUR BRANDS

1. NATURE-CIDE

The entire Nature-Cide line of products has 10 years of research and development behind it. All of these products have been proven effective in the field by licensed pest management professionals as well as by conducting third-party laboratory efficacy tests. One lab and field test conducted by The Journal of the Mosquito Association in 2019 shows one Nature-Cide product actually outperforms the top chemical products used every day for Mosquito control.

These products are currently being utilized for major commercial and residential use nationwide in professional pest control, hospitality, janitorial, transportation, and agriculture (Including cannabis cultivation). Nature-Cide is available to Pest Management Professionals through nationwide distribution such as Target Specialty Products, Veseris, Forshaw, Ensystex and more!

2. THERMAL-AID

Thermal-Aid all-natural products are clinically proven and patented therapeutic heating/cooling modalities designed explicitly for the medical field, to reduce swelling and relieve various pain issues. Thermal-Aid products cover a wide variety of needs for patients in all age groups for a gamut of ailments including but not limited to arthritis, fibromyalgia, multiple sclerosis, migraines, back pain, and muscle aches. Thermal-Aid products have a strong e-commerce presence and can also be found in various OTC pharmacy outlets and qualify for patient insurance reimbursement and FSA programs throughout the United States.

3. MALIBU BRANDS

Malibu Brands is a premium, homeopathic lifestyle brand. Malibu Brands’ first product is the Pacific Pain Relief Cream, which is a proven, natural topical analgesic cream for the temporary relief of various pains including arthritis, joint, muscle, headache, and migraine pain. The Malibu Brands “Pacific Pain Relief Cream ” can currently be found in various e-commerce venues. Malibu Brands is working to expand its product footprint with multiple products in development. Additionally, the Malibu Brands division is planning to embark on designing a unique clothing line that uses alternative sustainable materials such as hemp fiber and bamboo as they become readily available.

Investors

4/15/20: Raised $2,837,200 for working capital through 506(c).
5/21/2020: Raised $12,135 for working capital through Reg CF.
4/22/21: Raised $2,881,602 for working capital through 506(c).
10/01/21: Raised $2,987,199 for working capital through 506(c).
10/19/22: Raised $1,071,500 for working capital through 506(c).

Terms

This is an offering of Common Stock, under registration exemption 4(a)(6), in Med-X, Inc. Up to $3,000,000 in Common Stock may be raised at $0.25 per share with a minimum target amount of $10,000.

The offering deadline is May 31st, 2023. Unless the Company raises at least the Target Offering Amount of $10,000 under the Regulation CF offering by the Offering Deadline, no securities will be sold in this Offering, investment commitments will be cancelled, and committed funds will be returned.

Target Amount: $10,000 | 40,000 shares
Maximum Amount: $3,000,000 | 12,000,000 shares
Type of Security: Common Stock
Price/Share: $0.25
Minimum Investment: $500

Risks

As an investor, please be sure to read and review the Offering Statement. If you have any unanswered questions, please be sure to utilize the communication channel on this page to ask the issuer questions.

A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment.

In making an investment decision, investors must rely on their examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature.

These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.

Neither PicMii Crowdfunding nor any of its directors, officers, employees, representatives, affiliates, or agents shall have any liability whatsoever arising from any error or incompleteness of fact or opinion in, or lack of care in the preparation or publication of, the materials and communication herein or the terms or valuation of any securities offering.

The information contained herein includes forward-looking statements. These statements relate to future events or future financial performance and involve known and unknown risks, uncertainties, and other factors that may cause actual results to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond the company’s control and which could, and likely will materially affect actual results, levels of activity, performance, or achievements. Any forward-looking statement reflects the current views with respect to future events and is subject to these and other risks, uncertainties, and assumptions relating to operations, results of operations, growth strategy, and liquidity. No obligation exists to publicly update or revise these forward-looking statements for any reason or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Security Type:

Equity Security

Price Per Share

$0.25

Shares For Sale

12,000,000

Post Money Valuation:

43,211,544

Investment Bonuses!

None.

Regulatory Exemption:

Regulation Crowdfunding – Section 4(a)(6)

Deadline:

May 31, 2023

Minimum Investment Amount:

$500

Target Offering Range:

$10,000-$3,000,000

*If the sum of the investment commitments does not equal or exceed the minimum offering amount at the offering deadline, no securities will be sold and investment commitments will be cancelled returned to investors.


Matthew Mills
CEO & Chairman
BackgroundMatthew Mills is currently Chairman of the Board and CEO as well as the Company’s visionary. He utilizes and implements his vast experience and knowledge in product development, operations, business development, manufacturing, marketing, and crowdfunding to position the company for short-term and long-term growth.

Ronald Tchorzewski
CFO & Director
BackgroundCFO and Director of Med-X, Inc. since inception. Ron has over thirty-five years of experience in financial accounting for start-up and development comapnies, as well as reporting for publicly held companies from Silicon Valley and beyond. His Chief Financial Officer level support, including business plan development , capital structure, and day-to-day accounting experience positions Med-X, Inc. for financial success.

Jennifer Mills
President & Director
BackgroundJennifer Mills has been the Director and Corporate Secretary of Med-X, Inc. since its inception and named President in 2021. Jennifer has worked for multiple companies in her career as a high-level accounting liaison as well as in Human Resources and Project Management.

Nick Phillips
Chief Media Officer
BackgroundNick Phillips began is career in the Hollywood entertainment world and moved into digital marketing for multiple products in Los Angeles, which led him to The Marijuana Times. He drives The Marijuana Times digital magazine to fill a void in the reporting of the cannabis industry by providing a voice, education, and news about the cannabis community. Hi skill-set coupled with his dedication and attention to detail gives The Marijuana Times the leading edge in the industry.

Dr. Allan Kurtz
Director
BackgroundDr. Allan Kurtz is board-certified in internal medicine and has owned and operated Allan Kurtz, a Professional Medical Corporation since 1986. Dr. Kurtz has been the Medical Director of Warner Medical Center and the California Center of Longevity Medicine. He is also a long-time member of the American Osteopathic College of Internal Medicine.

Dr. Morton Hyson
Director
BackgroundDr. Morton Hyson is in private practice as a Board-certified Neurologist in Las Vegas, Nevada. He is also a Clinical Assistant Professor at Touro University in San Francisco, CA, where he has been educating since September 2000. His professional Associations include the American Medical Association, the American Academy of Neurology, the American Academy of Neurological and Orthopedic Surgeons, the American Headache Society.

Frederick Dashiell, Jr.
Director
BackgroundDr. Frederick Dashiell has held various teaching positions at educational institutions such as Chapman University in Orange, CA, University of California at Los Angeles, and California Institute of Technology. Frederick has also had various positions as a computer scientist as well as research scientist in the private sector. Frederick received a Bachelor of Science degree in physics from the University of North Carolina at Chapel Hill in 1963 and a Ph.D. in mathematics from the University of California at Berkeley in 1973.

Dr. David Toomey
CSO & Director
BackgroundDr. David Toomey has spent his professional life as a family physician for more than 24 years and as a Hospice Medical Director for the last decade. Over his many years as a physician, Dr. Toomey has also worked as a clinical investigator, developing and running clinical trials for multiple companies, including major pharmaceutical firms.

Michael Kuntz
Director
BackgroundMr. Kuntz is currently Managing Director of Young America Capital, a boutique investment bank focused exclusively on middle- market growth companies, a position that he has held since 2016.

Legal Company Name

Med-X Inc

Location

8236 Remmet Avenue
Canoga Park, California 91304

Number of Employees

15

Incorporation Type

C-Corp

State of Incorporation

Nevada

Date Founded

February 24, 2014

  • Last active: 1 year ago
  • 9 members
  • 0 posts
Med-X Inc
  • Group
  • Nick Phillips
  • KEY INVESTMENT POINTS

    Record Growth in 2022. Company saw 80% growth in revenue in 2022.Planning an IPO in 2023 to gain access to committed $100MM in growth capital from Global Emerging Markets.Reserved Nasdaq ticker symbol (MXRX).Pesticide regulations continue to tighten around the world.Climate changes increasing need for innovative pest control solutions.Mosquitos becoming resistant to traditional chemical-based solutions. In January 2023 the Nature-Cide division attended the Target Specialty Products / multi-billion dollar Rentokil North America National Sales Meeting and the division is already beginning to see the effects of the multi-billion dollar Rentokil Initial – Terminix merger that took place in late 2022. The Nature-Cide division is already staging registration into all of the Caribbean islands. The Nature-Cide division is also expecting to start the same process into Latin America as well as being approved on the Terminix and multi-billion dollar Rentokil North America’s Approved Product List (APL) in early to mid-2023, which should lead the Nature-Cide division into thousands of service trucks nationally.

    $100M Commitment of Growth Captial from Global Emerging Markets (GEM)

    In late 2021 the Company secured a $100 million capital commitment from Global Emerging Markets, a Luxembourg-based alternative investment group. Due to the Company's continued revenue growth the investment banking community has recognized the continued demand for the Med-X product selection as well as large investor demand to participate in investment strategies that make an impact on health and ecology. The company investor base has surpassed 3,800 shareholders who have supported the Company’s mission since inception. Now that the Company has secured large scale capital to advance the business model, management is negotiating with the investment banking community to Underwrite an Initial Public Offering. Now you can join the Green Scene movement that is making a difference in the areas of Health, Wellness and Ecology everyday, while management prepares the Company for expansion. This round of Regulation Crowdfunding will continue to support revenue growth of its brand portfolio, help position the Nature-Cide brand into the demanding world-wide markets while developing exciting new products and pursue acquisition opportunities, as the Company continues to draw awareness of the overuse of toxic synthetic chemicals and addictive pharmaceutical products.
Hello startup investors! Please use this communication channel to discuss the offering and ask Med-X any questions you may have regarding the offering.
Please sign up or log in to comment.


Bookmarks

Educational Material

Regulation
March 15, 2021

Make Way Venture Capitalists – SEC Updates Regulation Crowdfunding

Some Background It is no secret that venture capitalists dominate the startup space. Most startups move forward at the whim of venture capitalists just to survive. And just as you…
Regulation
February 15, 2021

The Form C

Form C - Everything You Need to Know Form C is a critical step in the crowdfunding process for all companies raising under Regulation Crowdfunding. Form C is a disclosure…
Types of SecuritiesGeneral
March 17, 2020

Types Of Securities

Types Of Securities Why do I care about the different security types available to me? Now that you are finding your inner venture capitalist, its critical that you understand what…